X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs STERLING BIOTECH - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA STERLING BIOTECH GSK PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 66.8 -0.6 - View Chart
P/BV x 11.7 0.0 52,775.0% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 GSK PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
STERLING BIOTECH
Dec-13
GSK PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,83811 36,552.4%   
Low Rs2,6373 77,558.8%   
Sales per share (Unadj.) Rs354.226.8 1,321.3%  
Earnings per share (Unadj.) Rs39.8-15.0 -265.9%  
Cash flow per share (Unadj.) Rs42.9-5.5 -784.8%  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.954.9 431.7%  
Shares outstanding (eoy) m84.70267.87 31.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.10.3 3,525.6%   
Avg P/E ratio x81.4-0.5 -17,521.7%  
P/CF ratio (eoy) x75.5-1.3 -5,936.0%  
Price / Book Value ratio x13.70.1 10,790.0%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,2161,862 14,729.4%   
No. of employees `0004.71.4 346.9%   
Total wages/salary Rs m4,830547 883.3%   
Avg. sales/employee Rs Th6,387.05,303.3 120.4%   
Avg. wages/employee Rs Th1,028.3403.8 254.6%   
Avg. net profit/employee Rs Th717.1-2,959.0 -24.2%   
INCOME DATA
Net Sales Rs m30,0007,181 417.8%  
Other income Rs m72843 1,709.4%   
Total revenues Rs m30,7287,223 425.4%   
Gross profit Rs m4,190947 442.5%  
Depreciation Rs m2632,543 10.3%   
Interest Rs m04,377 0.0%   
Profit before tax Rs m4,655-5,931 -78.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744-1,924 -90.6%   
Profit after tax Rs m3,368-4,007 -84.1%  
Gross profit margin %14.013.2 105.9%  
Effective tax rate %37.532.4 115.5%   
Net profit margin %11.2-55.8 -20.1%  
BALANCE SHEET DATA
Current assets Rs m16,74214,335 116.8%   
Current liabilities Rs m7,20249,809 14.5%   
Net working cap to sales %31.8-494.0 -6.4%  
Current ratio x2.30.3 807.7%  
Inventory Days Days52403 12.8%  
Debtors Days Days21171 12.2%  
Net fixed assets Rs m8,63555,432 15.6%   
Share capital Rs m847268 316.2%   
"Free" reserves Rs m19,22213,935 137.9%   
Net worth Rs m20,06914,701 136.5%   
Long term debt Rs m109,478 0.1%   
Total assets Rs m30,03873,988 40.6%  
Interest coverage xNM-0.4-  
Debt to equity ratio x00.6 0.1%  
Sales to assets ratio x1.00.1 1,029.1%   
Return on assets %11.20.5 2,238.5%  
Return on equity %16.8-27.3 -61.6%  
Return on capital %25.5-6.4 -396.2%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m5281,860 28.4%   
Fx outflow Rs m7,19325 28,899.2%   
Net fx Rs m-6,6651,835 -363.2%   
CASH FLOW
From Operations Rs m2,3601,719 137.3%  
From Investments Rs m3,008-3,148 -95.5%  
From Financial Activity Rs m-5,1081,426 -358.2%  
Net Cashflow Rs m260-3 -7,655.9%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.0 -  
FIIs % 23.8 9.9 240.4%  
ADR/GDR % 0.0 16.9 -  
Free float % 15.4 39.3 39.2%  
Shareholders   102,036 21,482 475.0%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jun 25, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS